In COPD GOLD, which statement is true regarding initial pharmacologic management for a patient in Combined Assessment Category A?

In COPD GOLD, which statement is true regarding initial pharmacologic management for a patient in Combined Assessment Category A?

• A. LABA
• B. LAMA
• C. Inhaled corticosteroid
• D. SAMA/SABA

Answer: (D)

In this category, the goal is rapid symptom relief with the least exposure to long-term therapy. For patients with COPD who are classified as Category A (low risk of exacerbations and fewer symptoms), the initial pharmacologic management is a short-acting inhaled bronchodilator used as needed. A SABA or SAMA inhaler provides quick bronchodilation and relief without the ongoing effects or potential side effects of long-acting therapies. If symptoms persist despite PRN use, stepping up to a long-acting bronchodilator (LAMA or LABA) can be considered. Inhaled corticosteroids are not first-line in Category A due to the low risk of exacerbations and potential steroid-related side effects, unless there are other indications. Therefore, using a short-acting bronchodilator as needed is the best initial approach.

In this category, the goal is rapid symptom relief with the least exposure to long-term therapy. For patients with COPD who are classified as Category A (low risk of exacerbations and fewer symptoms), the initial pharmacologic management is a short-acting inhaled bronchodilator used as needed. A SABA or SAMA inhaler provides quick bronchodilation and relief without the ongoing effects or potential side effects of long-acting therapies. If symptoms persist despite PRN use, stepping up to a long-acting bronchodilator (LAMA or LABA) can be considered. Inhaled corticosteroids are not first-line in Category A due to the low risk of exacerbations and potential steroid-related side effects, unless there are other indications. Therefore, using a short-acting bronchodilator as needed is the best initial approach.